CURRENT RECRUITING TRIALS
ALN APP-001 (Early AD)
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single intrathecal (IT) doses of ALN-APP in adult patients with early-onset Alzheimer’s Disease (EOAD).
AUTONOMY (Early AD)
A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)
Alzheimer’s disease (AD) is a fatal neurodegenerative disease that is manifested by progressive cognitive deficits including memory loss followed by loss of independent function as well as neuropsychiatric symptoms such as apathy, depression, anxiety, agitation and psychosis. JNJ-63733657 is a humanized monoclonal anti-tau antibody which binds to phosphorylated tau (P-tau).
The study will evaluate whether JNJ-63733657 can slow clinical (cognitive and functional) decline in participants with Early AD with evidence of elevated brain tau (T+) and assess its safety and tolerability.
GENFI (FTD)
Genetic Frontotemporal Dementia Initiative 2
From genfi.org.:
The aim of the study is to understand more about genetic FTD, particularly in those who have mutations in the progranulin (GRN), microtubule-associated protein tau (MAPT) and chromosome 9 open reading frame 72 (C9ORF72) genes. There are now promising avenues for treatment of these disorders but we still do not know when drugs should be started or how we should measure the response to treatment.
GENFI investigates both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry an abnormal genetic mutation. By studying these individuals who are destined to develop the disease later in life we can understand the development from the very earliest changes. The key objectives of GENFI are therefore to develop markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked.
The eventual aim will be to use these markers in future clinical trials of drugs in genetic FTD.
ION717 (Creutzfeldt-Jakob, Prion)
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
PASSAGE BIO upliFT-D (FTD)
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain.
This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the progranulin gene (FTD-GRN).
CONTACT US
For information on our trials, contact us at neurocog-cru.neuro@mcgill.ca.
ABOUT OUR STUDIES
PASSAGE BIO: FTD
INHANCE: Cognitive Training
AUTONOMY: Early Alzheimer
THE TEAM
Dr Simon Ducharme
Principal Investigator
The team
Dr. Etienne de Villers-Sidani
Principal Investigator
ACTIVE (NOT RECRUITING) TRIALS
CELIA (MCI)
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most.
To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB.
- Clinicians use the CDR-SB to measure several categories of dementia symptoms.
- The results for each category are added together for a total score. Lower scores are better.
Researchers will also learn more about the safety of BIIB080.
Romina Perrotti
Team Lead, Sr. Research Coordinator
Niloofar Barzegar
Clinical Research Coordinator